• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Penumbra (PEN) Revenue Climb Meets Profit Squeeze And Premium Valuation

    Simply Wall St·08/01/2026 00:24:03
    Listen to the news

    Penumbra walked into this earnings print priced for perfection, with the stock on a rich 78.8x P/E and trading above an indicated discounted cash flow estimate of US$280.42. The immediate reaction was muted, with the share price up only 0.4% after the release. That small move hides the real story. Quarterly revenue reached US$390.0m and basic earnings per share were US$0.88, solid numbers that keep the focus squarely on whether this medical equipment specialist can keep justifying such a full valuation.

    Impressed by Penumbra’s revenue and earnings per share, but uneasy about paying such a full P/E multiple for growth you need to be sure of? Consider balancing your watchlist with our 19 high quality undiscovered gems.

    Q2 2026 Earnings Summary

    • Revenue (Q2 2026 vs. Q2 2025): US$390.0m vs. US$339.5m (up about 15%)
    • Net Income, excl. extra items (Q2 2026 vs. Q2 2025): US$34.8m vs. US$45.3m (down about 23%)
    • Basic EPS (Q2 2026 vs. Q2 2025): US$0.88 vs. US$1.17 (down about 25%)
    • Trailing 12 month Net Profit Margin (TTM Net Income / TTM Revenue): 10.7% vs. 11.5% in the prior year (margin compression of about 0.8 percentage points)

    Tired of scrolling through earnings tables and raw figures trying to piece together what Penumbra’s results really mean for the stock? Get a clear, visual view of the company’s valuation and how the market is pricing its growth in our company report for Penumbra.

    NYSE:PEN Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026
    NYSE:PEN Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026

    Penumbra Bull Case Hinges On Execution, Not Hype

    The bullish story around Penumbra centers on CAVT, or computer assisted vacuum thrombectomy, gaining share in venous thromboembolism and stroke, lifting revenue, margins and cash generation over several years. The latest quarter supports parts of that story. Revenue reached US$390.0m, consistent with a business that is adding procedures and accounts in thrombectomy and embolization. Recent FDA and CE clearances for the THUNDERBOLT stroke system, plus launch of the FORWARD study into distal stroke, show Penumbra hitting important product and clinical milestones that can broaden its addressable patient pool.

    At the same time, the bullish view also leans on margin expansion. Here, the evidence is weaker. Net income and EPS declined year on year and the trailing 12 month net margin compressed to 10.7%. That suggests higher operating costs and deal related spending are still outrunning efficiency gains for now.

    Compare Penumbra’s new stroke systems and expanding thrombectomy footprint with how institutional analysts are setting their price goals. See the consensus price target analysis for Penumbra to gauge whether Wall Street thinks this operational story still supports today’s valuation.

    Penumbra Bear Case Focuses On Missed Profit Milestones

    The bearish view on Penumbra argues that heavy commercial and deal related spending might not scale efficiently, which would cap margins even if thrombectomy and embolization volumes keep growing. Q2 results give that concern real weight. Revenue of US$390.0m fits the story of strong procedural activity, yet net income excluding extra items fell to US$34.8m and basic EPS dropped to US$0.88. The trailing 12 month net margin eased to 10.7%. That is exactly the type of margin pressure skeptics have warned about.

    Bears also worry that the Boston Scientific transaction and recent clinical wins could distract from cost discipline. The continued margin compression after a similar pattern in Q1, alongside deal related expenses and no forward guidance, looks like a milestone missed on proving that Penumbra can translate its stroke and embolization momentum into cleaner earnings leverage.

    With Penumbra trading on a rich P/E and margins easing, the key question is whether its balance sheet and cash flows comfortably support this valuation. You can review the underlying liquidity, debt and cash runway in our financial health analysis of Penumbra stock.

    Stay Ahead With Penumbra And Beyond

    If Penumbra’s rich P/E, margin pressure and product milestones have your attention, register for free with Simply Wall St and add it to a Watchlist so you can track the share price against fair value and watch for an entry point that fits your plan. Once you are invested, use the Portfolio Command Center to cut through noise and get focused updates on valuation shifts, earnings and key company events. For a broader view, tap into the Community and see how other investors are thinking about opportunities and risks. This way you can spot potential catalysts and red flags early and stay ahead of the market.

    Seeking Alternatives Beyond Penumbra?

    Fresh stock ideas can start breaking out while you are still focused on Penumbra. Momentum can shift quickly and early data can become stale under the radar, so acting promptly may be important for some investors.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.